EVgo Inc (NASDAQ:EVGO) reported that fourth-quarter sales nearly quadrupled year-on-year to $27.30 million, beating the consensus of $21.82 million. EVgo’s…
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003